Research and Markets: Proteasome Inhibitors Market - 2013 Report Examines Amgen's Acquisition of Onyx and Takeda's Acquisition of Millennium and Volun

28-10-2013 Business Wire HealthComments (0)

AmgenOnyx PharmaceuticalsPharmaceutical

Research and Markets ( has announced the addition of the "Proteasome Inhibitors Market" report to their offering. The market for proteasome inhibitors is experiencing rapid transformation. Amgen's acquisition of Onyx Pharmaceuticals, developer of Kyprolis, for $10.4 billion comes just five years after Takeda paid $8.8 billion for Millennium Pharmaceuticals, developer of Velcade, the first in class. Growing evi

Read more on Business Wire Health

More on this story...

Onyx Pharma accepts increased bid from Amgen

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top